Werfen reported that the GEM Premier 7000 ABG analyzer safely and effectively accepts a capillary draw to detect hemolysis in NICU patients with rates ranging from 39.6 to 46.4 percent.
Published
Signal category
Products & Services
Quote
“For babies in the NICU, an ABG analyzer that will safely and effectively accept a capillary draw to detect hemolysis (rates in the NICU ranging from 39.6 -46.4 %)”
— Jordan Helfen|Werfen team
Company
- Industry
- Medical Equipment Manufacturing
- Location
- L'Hospitalet de Llobregat, ES
- Company size
- 6,833 employees
Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain. We are a worldwide leader in specialized diagnostics in the areas of Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. We operate directly in 30 countries, and in more than 100 territories through distributors. Our headquarters are in Barcelona, Spain and our Technology Centers are located in the United States and Europe. Worldwide sales in 2024 were almost € 2.2 billion and our workforce is 7,000 strong.